Augmedix (Augmedix) ROCE % : -52.27% (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Augmedix ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Augmedix's annualized ROCE % for the quarter that ended in Dec. 2023 was -52.27%.

Augmedix ROCE % Historical Data

The historical data trend for Augmedix's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Augmedix ROCE % Chart

Augmedix Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

-545.60

-197.41

-61.23

-86.50

-58.42

Augmedix Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
ROCE %	Get a 7-Day Free Trial												-115.89	-125.40	-91.05	-76.06	-52.27

Augmedix ROCE % Calculation

Augmedix's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-16.773	/	( ( (33.641 - 19.314)	+	(66.712 - 23.618) )	/ 2 )
	=	-16.773	/	( (14.327	+	43.094)	/ 2 )
	=	-16.773	/	28.7105
	=	-58.42 %

Augmedix's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	-15.48	/	( ( (40.833 - 24.701)	+	(66.712 - 23.618) )	/ 2 )
	=	-15.48	/	( ( 16.132	+	43.094 )	/ 2 )
	=	-15.48	/	29.613
	=	-52.27 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

Augmedix (NAS:AUGX) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Augmedix ROCE % Related Terms

Thank you for viewing the detailed overview of Augmedix's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Augmedix (Augmedix) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Augmedix Inc (NAS:AUGX) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

111 Sutter Street, Suite 1300, San Francisco, CA, USA, 94104

Website

https://www.augmedix.com

Augmedix Inc is engaged in ambulatory/clinical/hospital segments of the U.S. patient care services market with products that address medical note documentation needs. The company's products cater to large and small healthcare organizations but can also be adopted by individual practitioners. The company's revenues consist of service fees charged to its customers to subscribe to the company's remote medical documentation and clinical support products.

Executives

Paul Ginocchio	officer: Chief Financial Officer	C/O AUGMEDIX, INC., 111 SUTTER STREET, SUITE 1300, SAN FRANCISCO CA 94104
Redmile Group, Llc	director, 10 percent owner	ONE LETTERMAN DRIVE, BUILDING D, SUITE D3-300, SAN FRANCISCO CA 94129
Margie L. Traylor	director	5130 E. CASCALOTE DR, CAVE CREEK AZ 85331
Redco Ii Master Fund, L.p.	director, 10 percent owner	ONE LETTERMAN DRIVE, BLDG D, STE D3-300, SAN FRANCISCO CA 94129
Robert C. Faulkner	director	C/O REDMILE GROUP, ONE LETTERMAN DRIVE, BUILDING D, SUITE D, SAN FRANCISCO CA 94129
Roderick H. O'reilly	director	C/O CHANGE HEALTHCARE INC., 3055 LEBANON PIKE, SUITE 1000, NASHVILLE TN 37214
Mckesson Ventures, Llc	director, 10 percent owner	ONE POST STREET, SAN FRANCISCO CA 94104
William J Febbo	director	600 CALIFORNIA ST., 9TH FLOOR, SAN FRANCISCO CA 94108
Jonathan Hawkins	officer: Chief Revenue Officer	C/O AUGMEDIX, INC., 1161 MISSION STREET, SUITE LL, SAN FRANCISCO CA 94103
Sandra Breber	officer: CHIEF OPERATING OFFICER	C/O AUGMEDIX, INC., 1161 MISSION STREET, SUITE LL, SAN FRANCISCO CA 94103
Ian Shakil	officer: CHIEF STRATEGY OFFICER	C/O AUGMEDIX, INC., 1161 MISSION STREET, SUITE LL, SAN FRANCISCO CA 94103
Emmanuel Krakaris	director, officer: PRESIDENT, CEO, AND SECRETARY	C/O AUGMEDIX, INC., 1161 MISSION STREET, SUITE LL, SAN FRANCISCO CA 94103
Saurav Chatterjee	officer: CHIEF TECHNOLOGY OFFICER	C/O AUGMEDIX, INC., 1161 MISSION STREET, SUITE LL, SAN FRANCISCO CA 94103
Laurie Mcgraw	director	4720 E COTTON GIN LOOP, SUITE 220, C/O MEDAVAIL HOLDINGS, INC., PHOENIX AZ 85040
Jason Krikorian	director, 10 percent owner	C/O AUGMEDIX, INC., 1161 MISSION STREET, SUITE LL, SAN FRANCISCO CA 94103